Syndecan-1 (CD138) Modulates Triple-Negative Breast Cancer Stem Cell Properties via Regulation of LRP-6 and IL-6-Mediated STAT3 Signaling.
- Citation:
- SA, I., H. H, V. L,, Jouini R, and et al,
"Syndecan-1 (CD138) Modulates Triple-Negative Breast Cancer Stem Cell Properties via Regulation of LRP-6 and IL-6-Mediated STAT3 Signaling.",
PLoS One, vol. 8(12):e85737. , 2013.